Yusuf Yılmaz

28.5k total citations · 4 hit papers
214 papers, 6.9k citations indexed

About

Yusuf Yılmaz is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Yusuf Yılmaz has authored 214 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 155 papers in Epidemiology, 64 papers in Hepatology and 48 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Yusuf Yılmaz's work include Liver Disease Diagnosis and Treatment (153 papers), Diet, Metabolism, and Disease (39 papers) and Liver Disease and Transplantation (37 papers). Yusuf Yılmaz is often cited by papers focused on Liver Disease Diagnosis and Treatment (153 papers), Diet, Metabolism, and Disease (39 papers) and Liver Disease and Transplantation (37 papers). Yusuf Yılmaz collaborates with scholars based in Türkiye, United States and Italy. Yusuf Yılmaz's co-authors include Zobair M. Younossi, Vincent Wai‐Sun Wong, Elisabetta Bugianesi, Jacob George, Fatih Eren, Eda Kaya, Ramazan Kurt, Oya Yönal, Jian‐Gao Fan and Marco Arrese and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Yusuf Yılmaz

192 papers receiving 6.8k citations

Hit Papers

Global Perspectives on Nonalcoholic Fatty Liver Disease a... 2018 2026 2020 2023 2018 2018 2023 2024 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    2018 1.4k citations Zobair M. Younossi, Yusuf Yılmaz et al. profile →
  2. Nonalcoholic Steatohepatitis Is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
    2018 603 citations Zobair M. Younossi, Maria Stepanova et al. profile →
  3. Recompensation in cirrhosis: unravelling the evolving natural history of nonalcoholic fatty liver disease
    2023 99 citations Yusuf Yılmaz, Zobair M. Younossi et al. profile →
  4. Prevalence of metabolic dysfunction‐associated steatotic liver disease in the Middle East and North Africa
    2024 43 citations Zobair M. Younossi, James M. Paik et al. Liver International profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yusuf Yılmaz Türkiye 43 5.1k 2.1k 2.0k 1.2k 993 214 6.9k
Kathleen E. Corey United States 44 4.8k 0.9× 2.5k 1.2× 1.9k 0.9× 962 0.8× 1.3k 1.3× 167 7.0k
Laura Wilson United States 34 4.9k 1.0× 1.9k 0.9× 2.0k 1.0× 744 0.6× 1.0k 1.1× 105 6.4k
Anna Ludovica Fracanzani Italy 59 6.2k 1.2× 2.6k 1.3× 2.5k 1.2× 1.2k 1.0× 1.1k 1.1× 217 9.4k
Yuichiro Eguchi Japan 40 4.8k 0.9× 3.0k 1.4× 1.6k 0.8× 981 0.8× 1.0k 1.0× 178 6.7k
Per Stål Sweden 35 6.0k 1.2× 3.6k 1.8× 2.2k 1.1× 825 0.7× 948 1.0× 135 7.7k
Mariana Verdelho Machado Portugal 36 4.9k 1.0× 1.8k 0.9× 1.9k 0.9× 2.1k 1.7× 927 0.9× 90 6.7k
Sven Francque Belgium 48 7.3k 1.4× 3.2k 1.5× 2.9k 1.4× 1.5k 1.2× 1.5k 1.5× 194 9.1k
Masahide Hamaguchi Japan 41 4.0k 0.8× 1.2k 0.6× 2.7k 1.3× 1.1k 0.9× 879 0.9× 280 8.1k
Schuyler O. Sanderson United States 33 7.4k 1.5× 4.1k 2.0× 2.7k 1.3× 1.1k 0.9× 1.5k 1.6× 58 9.4k
Mohammed Eslam Australia 37 8.4k 1.7× 3.9k 1.9× 3.3k 1.6× 1.5k 1.2× 1.1k 1.1× 123 9.6k

Countries citing papers authored by Yusuf Yılmaz

Since Specialization
Citations

This map shows the geographic impact of Yusuf Yılmaz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yusuf Yılmaz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yusuf Yılmaz more than expected).

Fields of papers citing papers by Yusuf Yılmaz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yusuf Yılmaz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yusuf Yılmaz. The network helps show where Yusuf Yılmaz may publish in the future.

Co-authorship network of co-authors of Yusuf Yılmaz

This figure shows the co-authorship network connecting the top 25 collaborators of Yusuf Yılmaz. A scholar is included among the top collaborators of Yusuf Yılmaz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yusuf Yılmaz. Yusuf Yılmaz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaya, Eda, Eduardo Vilar‐Gómez, Raj Vuppalanchi, & Yusuf Yılmaz. (2025). Body mass index and diabetes predict severity of liver fibrosis across the spectrum of steatotic liver disease. Annals of Hepatology. 30(1). 101907–101907.
2.
Zelber‐Sagi, Shira, James M. Paik, Dana Ivancovsky‐Wajcman, et al.. (2025). “Weekend Warrior” Exercise Pattern Protects Against MASLD and Mortality Comparable to Regular Exercise: National Cohort Study. Liver International. 45(8). e70226–e70226. 1 indexed citations
3.
4.
5.
Holland‐Fischer, Peter, Jesper Bach Hansen, Yusuf Yılmaz, et al.. (2025). Clinical and Biochemical Characteristics of a Danish and Turkish Cohort of Incident and Prevalent Patients with Primary Biliary Cholangitis. The Turkish Journal of Gastroenterology. 36(4). 241–246. 2 indexed citations
6.
Kaya, Eda & Yusuf Yılmaz. (2024). Association of Metabolic Dysfunction-Associated Fatty Liver Disease with Cognitive Impairment and All-Cause Dementia: A Comprehensive Review. The Turkish Journal of Gastroenterology. 35(2). 76–82. 3 indexed citations
7.
Kaya, Eda & Yusuf Yılmaz. (2024). Deciphering the implications of the MAFLD and MASLD definitions in the NAFLD population: Results from a single-center biopsy study. Zeitschrift für Gastroenterologie. 62(1). e16–e16. 1 indexed citations
8.
9.
Kani, Haluk Tarık, et al.. (2022). Evaluation of spleen stiffness in healthy population: a vibration-controlled transient elastography study. Journal of Health Sciences and Medicine. 5(2). 689–692. 1 indexed citations
10.
Yılmaz, Yusuf, et al.. (2022). Impairment of patient‐reported outcomes among patients with non‐alcoholic fatty liver disease: a registry‐based study. Alimentary Pharmacology & Therapeutics. 57(2). 215–223. 12 indexed citations
11.
Kani, Haluk Tarık, et al.. (2021). Evaluation of the Impact of Metabolic Syndrome on Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease. The Turkish Journal of Gastroenterology. 32(8). 661–666. 9 indexed citations
12.
Kaya, Eda, et al.. (2021). Feasibility of Fibroscan in Assessment of Hepatic Steatosis and Fibrosis in Obese Patients: Report From a General Internal Medicine Clinic. The Turkish Journal of Gastroenterology. 32(5). 466–472. 11 indexed citations
13.
Kaya, Eda & Yusuf Yılmaz. (2019). Non-alcoholic fatty liver disease: A growing public health problem in Turkey. The Turkish Journal of Gastroenterology. 30(10). 865–871. 37 indexed citations
14.
Yılmaz, Yusuf, et al.. (2019). Growing burden of nonalcoholic fatty liver disease in Turkey: A single-center experience. The Turkish Journal of Gastroenterology. 30(10). 892–898. 22 indexed citations
15.
Deyneli, Oğuzhan, et al.. (2018). Screening for hepatic fibrosis and steatosis in Turkish patients with type 2 diabetes mellitus: A transient elastography study. The Turkish Journal of Gastroenterology. 30(3). 266–270. 21 indexed citations
16.
Yönal, Oya, et al.. (2015). No association between the functional cannabinoid receptor type 2 Q63R variants and inflammatory bowel disease in Turkish subjects. The Turkish Journal of Gastroenterology. 25(6). 639–43. 10 indexed citations
17.
Sünbül, Murat, Tarık Kıvrak, Erdal Durmuş, et al.. (2015). Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovascular Therapeutics. 33(5). 294–299. 23 indexed citations
18.
Yılmaz, Yusuf, et al.. (2011). NONINVASIVE ASSESSMENT OF LIVER FIBROSIS WITH THE ASPARTATE TRANSAMINASE TO PLATELET RATIO INDEX (APRI): USEFULNESS IN PATIENTS WITH CHRONIC LIVER DISEASE. Hepatitis Monthly. 11(231). 103–107. 58 indexed citations
19.
Yılmaz, Yusuf, Yeşim Özen Alahdab, Oya Yönal, et al.. (2010). Microalbuminuria in nondiabetic patients with nonalcoholic fatty liver disease: association with liver fibrosis. Metabolism. 59(9). 1327–1330. 84 indexed citations
20.
Yılmaz, Yusuf, et al.. (2010). Kefir Improves the Efficacy and Tolerability of Triple Therapy in Eradicating Helicobacter pylori. Journal of Medicinal Food. 14(4). 344–347. 61 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kathleen E. Corey Breakdown of academic impact, for papers by Laura Wilson Breakdown of academic impact, for papers by Anna Ludovica Fracanzani Breakdown of academic impact, for papers by Yuichiro Eguchi Breakdown of academic impact, for papers by Per Stål Breakdown of academic impact, for papers by Mariana Verdelho Machado Breakdown of academic impact, for papers by Sven Francque Breakdown of academic impact, for papers by Masahide Hamaguchi Breakdown of academic impact, for papers by Schuyler O. Sanderson Breakdown of academic impact, for papers by Mohammed Eslam
Rankless by CCL
2026